KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Common Equity: 2009-2025

Historic Common Equity for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $77.4 million.

  • Arbutus Biopharma's Common Equity fell 27.59% to $77.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.4 million, marking a year-over-year decrease of 27.59%. This contributed to the annual value of $97.4 million for FY2024, which is 8.16% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Common Equity stood at $77.4 million, which was down 6.72% from $83.0 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Common Equity peaked at $169.4 million during Q4 2021, and registered a low of $77.4 million during Q3 2025.
  • For the 3-year period, Arbutus Biopharma's Common Equity averaged around $107.7 million, with its median value being $106.9 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 66.17% in 2021, then slumped by 32.24% in 2025.
  • Arbutus Biopharma's Common Equity (Quarterly) stood at $169.4 million in 2021, then fell by 19.23% to $136.9 million in 2022, then dropped by 22.53% to $106.0 million in 2023, then dropped by 8.16% to $97.4 million in 2024, then decreased by 27.59% to $77.4 million in 2025.
  • Its Common Equity stands at $77.4 million for Q3 2025, versus $83.0 million for Q2 2025 and $79.2 million for Q1 2025.